167 related articles for article (PubMed ID: 36082820)
21. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
22. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
23. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Klempner SJ; Myers AP; Mills GB; Westin SN
Expert Opin Pharmacother; 2013 Nov; 14(16):2171-82. PubMed ID: 23937415
[TBL] [Abstract][Full Text] [Related]
24. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
Saed GM; Fletcher NM; Diamond MP; Morris RT; Gomez-Lopez N; Memaj I
Gynecol Oncol; 2018 Mar; 148(3):567-575. PubMed ID: 29329880
[TBL] [Abstract][Full Text] [Related]
25. Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.
Lawal AO; Musekiwa A; Grobler L
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD009620. PubMed ID: 23740789
[TBL] [Abstract][Full Text] [Related]
26. [Discrimination and clinical value of plasma metabolomic profiles in multidrug resistant epithelial ovarian cancer].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):896-902. PubMed ID: 29262505
[No Abstract] [Full Text] [Related]
27. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer.
Li J; Jiang K; Qiu X; Li M; Hao Q; Wei L; Zhang W; Chen B; Xin X
BMB Rep; 2014 Jan; 47(1):33-8. PubMed ID: 24209634
[TBL] [Abstract][Full Text] [Related]
28. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
[TBL] [Abstract][Full Text] [Related]
29. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
30. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
31. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
Miao Y; Li S; Yan Q; Li B; Feng Y
Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
[TBL] [Abstract][Full Text] [Related]
33. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
Hou MM; Wang Z; Janku F; Piha-Paul S; Naing A; Hong D; Westin S; Coleman RL; Sood AK; Tsimberidou AM; Subbiah V; Wheler J; Zinner R; Lu K; Meric-Bernstam F; Fu S
Oncotarget; 2016 Jun; 7(23):35132-43. PubMed ID: 27147567
[TBL] [Abstract][Full Text] [Related]
34. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer.
Vidal A; Muñoz C; Guillén MJ; Moretó J; Puertas S; Martínez-Iniesta M; Figueras A; Padullés L; García-Rodriguez FJ; Berdiel-Acer M; Pujana MA; Salazar R; Gil-Martin M; Martí L; Ponce J; Molleví DG; Capella G; Condom E; Viñals F; Huertas D; Cuevas C; Esteller M; Avilés P; Villanueva A
Clin Cancer Res; 2012 Oct; 18(19):5399-411. PubMed ID: 22896654
[TBL] [Abstract][Full Text] [Related]
35. [Bioinformatics analysis of drug-resistant ceRNA in epithelial ovarian cancer].
Pan ZM; Tan FC; Chen CX; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2021 Feb; 56(2):121-130. PubMed ID: 33631884
[No Abstract] [Full Text] [Related]
36. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
Fletcher NM; Belotte J; Saed MG; Memaj I; Diamond MP; Morris RT; Saed GM
Free Radic Biol Med; 2017 Jan; 102():122-132. PubMed ID: 27890641
[TBL] [Abstract][Full Text] [Related]
37. Heat Shock Protein 60 (HSP60) Serves as a Potential Target for the Sensitization of Chemoresistant Ovarian Cancer Cells.
Harper AK; Fletcher NM; Fan R; Morris RT; Saed GM
Reprod Sci; 2020 Apr; 27(4):1030-1036. PubMed ID: 32124395
[TBL] [Abstract][Full Text] [Related]
38. iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer.
Pearl ML; Dong H; Zhao Q; Tulley S; Dombroff MK; Chen WT
Gynecol Oncol; 2017 Nov; 147(2):426-432. PubMed ID: 28830645
[TBL] [Abstract][Full Text] [Related]
39. Nintedanib for Advanced Epithelial Ovarian Cancer: A Change of Perspective? Summary of Evidence from a Systematic Review.
Barra F; Laganà AS; Ghezzi F; Casarin J; Ferrero S
Gynecol Obstet Invest; 2019; 84(2):107-117. PubMed ID: 30304728
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
